AI
VNDA icon

Analytic Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

Analytic Investors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$605K Buy
36,372
+10,389
+40% +$140K 0.01% 448
2016
Q2 		$291K Sell
25,983
-16,969
-40% -$164K ﹤0.01% 538
2016
Q1 		$359K Buy
+42,952
New +$353K ﹤0.01% 519

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Analytic Investors's VNDA Position: Q3 2016 in Review

Analytic Investors increased its Vanda Pharmaceuticals (VNDA) stake by 40% in Q3 2016, buying an estimated $140K and bringing the position to 36,372 shares worth $605K. The position accounts for 0.01% of the portfolio, ranked #448.

Analytic Investors first reported a position in VNDA in Q1 2016 and has held it in 3 quarters since. 140 funds tracked by Wall St. Rank hold VNDA as of Q3 2016.

  • Analytic Investors held 36,372 shares of Vanda Pharmaceuticals worth $605K as of Q3 2016.
  • Analytic Investors bought 10,389 Vanda Pharmaceuticals shares in Q3 2016, an estimated $140K.
  • Vanda Pharmaceuticals made up 0.01% of Analytic Investors's portfolio in Q3 2016, its #448 holding.
  • Analytic Investors first reported a position in Vanda Pharmaceuticals in Q1 2016 and has held it in 3 quarters since.
  • 140 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.